Macrogen Asia Pacific strives to enable everyone to lead happier and healthier lives by integrating knowledge of their genetics, healthcare, and lifestyle.
Next Generation Sequencing is the method of reading a genome by dividing it into many pieces, assembling the obtained sequence pieces and analyzing the sequence of the whole genome.
Capillary Electrophoresis Sequencing (CES) is a service that analyzes DNA sequences using a biochemical method.
Macrogen enables personalized diagnostics and treatments based on genetic tests such as for cancer genome, prenatal genome and rare disease genome.
Macrogen provides genomics services for research use, as well as clinical diagnostics worldwide, with laboratories in 6 countries, and more than 18,000 customers in 153 countries.
Research services include Next Generation Sequencing, Capillary Electrophoresis Sequencing, Microarrays, Transgenic mice, Oligonucleotide synthesis. Clinical services include hereditary cancer testing, somatic cancer panels, carrier testing, NIPT screening, clinical WGS and clinical WES.
Our laboratories participate in CAP Proficiency Testing, and 3 of our laboratories have received College of American Pathologists (CAP) accreditation. Our main laboratory also has certification by the Korean Institute of Genetic Testing Evaluation and NGS Clinical Laboratory Certification by the Korean Ministry of Food and Drug Safety.
On 5th June 2018, Macrogen Inc., a well-established genomics services provider with customers from over 150 countries, established its Asia Pacific subsidiary, Macrogen Asia Pacific Pte. Ltd., in Singapore.
Macrogen Asia Pacific Pte. Ltd. is the company’s second global operation in Asia following one in Japan. It is located in Biopolis, a biomedical research complex, and is aimed at expanding the genome sequencing and analysis market in Southeast Asia.
Inaugural Macrogen scientific conference co-hosted by NTU. 4 CME Points will be awarded.